Preclinical glioma studies show that CTLA-4 inhibitors promote CD4+ T cell proliferation and reduce Treg/CD4+ T cell ratios, correlating CTLA-4 expression with poor prognosis in glioblastoma (41, 42). This evidence concerns the gene CTLA4 and central nervous system cancer.